Fulltext

Antiretroviral Therapy Reduces Markers of Endothelial and Coagulation Activation in Patients Infected with Human Immunodeficiency Virus Type 1

Wolf, Katja ; Tsakiris, Dimitrios A. ; Weber, Rainer ; Erb, Peter ; Battegay, Manuel

In: The Journal of Infectious Diseases, 2002, vol. 185, no. 4, p. 456-462

Ajouter à la liste personnelle
    Titre
    • Antiretroviral Therapy Reduces Markers of Endothelial and Coagulation Activation in Patients Infected with Human Immunodeficiency Virus Type 1
    Auteur
    • Wolf, Katja. Basel Center for HIV Research, Outpatient Department of Internal Medicine, Basel
    • Tsakiris, Dimitrios A.. Haemostasis Laboratory, Department of Central Laboratories, University Hospital Basel, Basel
    • Weber, Rainer. Division of Infectious Diseases, University Hospital Zurich, Zurich, Switzerland
    • Erb, Peter. Institute of Medical Microbiology, University of Basel, Basel
    • Battegay, Manuel. Basel Center for HIV Research, Outpatient Department of Internal Medicine, Basel
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • The Journal of Infectious Diseases, 2002, vol. 185, no. 4, p. 456-462. The University of Chicago Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:294566
    Summary
    We investigated the effect of antiretroviral therapy on vascular activation in 41 human immunodeficiency (HIV)—infected patients receiving a regimen that included either at least 1 protease inhibitor (PI; n = 21) or a nonnucleoside reverse-transcriptase inhibitor (NNRTI; n = 20). Acontrol group of 21 healthy subjectswas included for comparison. Levels of endothelialmarkers (soluble vascular cell adhesion molecule [sVCAM]-1, soluble intercellular adhesionmolecule-1, and vonWillebrand factor) were higher in HIV-infected persons before treatment than in control subjects anddecreasedsignificantlyafter 5-13 months of treatment. Levels of sVCAM-1 and vonWillebrand factor correlated significantly with initial virus load. D-dimer concentrations also decreased significantly after initiation of treatment. PI- and NNRTI-containing regimens had similar effects. Therapy did not reduce levels of the soluble platelet (sP) activation markers sP-selectin and CD40 ligand. The inhibition of markers of vascular activation may counterbalance sequelae of therapy-induced dyslipidemia and potentially prevent development of atherosclerosis in HIVinfected patients